There are 2789 resources available
984P - Phase I dose escalation trial of nintedanib in combination with pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
Presenter: Capucine Baldini
Session: ePoster Display
947P - Updated survival and secondary safety and efficacy analyses from CA 209-678: A phase II open-label single-centre study of Y90-radioembolisation (Y90) in combination with nivolumab in Asian patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Joycelyn Lee
Session: ePoster Display
948P - Predicting the efficacy of lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC) using radiomics features of tumors extracted from baseline MRI
Presenter: Huichuan Sun
Session: ePoster Display
949P - Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)
Presenter: Liangrong Shi
Session: ePoster Display
950P - Ultra-sensitive and cost-effective method for early stage hepatocellular carcinoma and intrahepatic cholangiocarcinoma detection using plasma cfDNA fragmentomic profiles
Presenter: Xiangyu Zhang
Session: ePoster Display
8P - The characterization of tumors associated with the antitumor activity of lenvatinib plus anti-PD-1 antibody combination therapy in a mouse syngeneic model panel
Presenter: Yoichi Ozawa
Session: ePoster Display
9P - Click Activated Protodrugs Against Cancer (CAPAC) platform enhances the safety, pharmacokinetics, and antitumor efficacy of cancer therapies in vivo
Presenter: Sangeetha Srinivasan
Session: ePoster Display
10P - DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
Presenter: Hirokazu Suzuki
Session: ePoster Display
11P - Profiling adaptive responses of renal cell cancer to cabozantinib in order to develop rational drug combinations
Presenter: Diego Tosi
Session: ePoster Display
12P - The design and development of novel pentaranes: Paving the way to EMT inhibition in triple-negative breast cancer cells
Presenter: Alexander Scherbakov
Session: ePoster Display